Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of patients. A new all-oral, six-month treatment regimen is safer and more effective at treating multidrug-resistant tuberculosis (MDR-TB) than … Read more
LONDON – TB-PRACTECAL, a clinical trial led by Doctors Without Borders/Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) [1] than the currently accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who … Read more
BOSTON/PARIS — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and clinicians led by Doctors Without Borders/Médecins Sans Frontières (MSF), Partners In Health (PIH), and Interactive … Read more
LONDON – A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and more patient data was extremely unlikely to change the trial’s outcome. TB-PRACTECAL, a phase II/III clinical … Read more